Evidence map›Paper›PMID 38855447›Full record

ArticleFrontiers in public health2024

Genomic surveillance during the first two years of the COVID-19 pandemic - country experience and lessons learned from Türkiye.

Süleyman Yalçın, Yasemin Coşgun, Ege Dedeoğlu, Katharina Kopp, Fatma Bayrakdar, Gültekin Ünal, Biran Musul, Ekrem Sağtaş, Gülay Korukluoğlu, Philomena Raftery and 1 more

Abstract read
In one paragraph

Article in Frontiers in public health, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Süleyman YalçınNational Molecular Microbiology Reference Laboratory, Public Health General Directorate, Ministry of Health, Ankara, Türkiye.
Yasemin CoşgunDepartment of National Reference Laboratories and Biological Products, Public Health General Directorate, Ministry of Health, Ankara, Türkiye.
Ege DedeoğluWorld Health Organization Country Office, Ankara, Türkiye.
Katharina KoppWorld Health Organization Country Office, Ankara, Türkiye.
Fatma BayrakdarNational Molecular Microbiology Reference Laboratory, Public Health General Directorate, Ministry of Health, Ankara, Türkiye.
Gültekin ÜnalWorld Health Organization Country Office, Ankara, Türkiye.
Biran MusulWorld Health Organization Country Office, Ankara, Türkiye.
Ekrem SağtaşDepartment of National Reference Laboratories and Biological Products, Public Health General Directorate, Ministry of Health, Ankara, Türkiye.
Gülay KorukluoğluDepartment of Medical Microbiology, University Health Sciences, Ankara Bilkent City Hospital, Ankara, Türkiye.
Philomena RafteryWorld Health Organization Country Office, Ankara, Türkiye.
Sedat KaygusuzPublic Health General Directorate, Ministry of Health, Ankara, Türkiye.

Funding

World Health Organization 001
6 · The paper itself

Abstract

Background: Türkiye confirmed its first case of SARS-CoV-2 on March 11, 2020, coinciding with the declaration of the global COVID-19 pandemic. Subsequently, Türkiye swiftly increased testing capacity and implemented genomic sequencing in 2020. This paper describes Türkiye's journey of establishing genomic surveillance as a middle-income country with limited prior sequencing capacity and analyses sequencing data from the first two years of the pandemic. We highlight the achievements and challenges experienced and distill globally relevant lessons. Methods: We tracked the evolution of the COVID-19 pandemic in Türkiye from December 2020 to February 2022 through a timeline and analysed epidemiological, vaccination, and testing data. To investigate the phylodynamic and phylogeographic aspects of SARS-CoV-2, we used Nextstrain to analyze 31,629 high-quality genomes sampled from seven regions nationwide. Results: Türkiye's epidemiological curve, mirroring global trends, featured four distinct waves, each coinciding with the emergence and spread of variants of concern (VOCs). Utilizing locally manufactured kits to expand testing capacity and introducing variant-specific quantitative reverse transcription polymerase chain reaction (RT-qPCR) tests developed in partnership with a private company was a strategic advantage in Türkiye, given the scarcity and fragmented global supply chain early in the pandemic. Türkiye contributed more than 86,000 genomic sequences to global databases by February 2022, ensuring that Turkish data was reflected globally. The synergy of variant-specific RT-qPCR kits and genomic sequencing enabled cost-effective monitoring of VOCs. However, data analysis was constrained by a weak sequencing sampling strategy and fragmented data management systems, limiting the application of sequencing data to guide the public health response. Phylodynamic analysis indicated that Türkiye's geographical position as an international travel hub influenced both national and global transmission of each VOC despite travel restrictions. Conclusion: This paper provides valuable insights into the testing and genomic surveillance systems adopted by Türkiye during the COVID-19 pandemic, proposing important lessons for countries developing national systems. The findings underscore the need for robust testing and sampling strategies, streamlined sample referral, and integrated data management with metadata linkage and data quality crucial for impactful epidemiological analysis. We recommend developing national genomic surveillance strategies to guide sustainable and integrated expansion of capacities built for COVID-19 and to optimize the effective utilization of sequencing data for public health action.

Indexed as

COVID-19SARS-CoV-2Genome, ViralGenomicsHumansMalePandemicsCOVID-19genomic surveillancenext generation sequencing (NGS)public healthsevere acute respiratory syndrome coronavirus 2

Identifiers

PMID38855447
PMCPMC11160438

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.